ZOLADEX DEPOT Injection / Subcutaneous

Goserelin
3.6mg
AstraZeneca UK Limited
Pack size 1 Syringe (Single Dose Safe System)
Dispensing mode POM
Source UK
AgentModern Pharmaceutical Co.
Retail Price 640.00 AED

Indications

ZOLADEX DEPOT Injection / Subcutaneous is used for: Palliative treatment of prostatic carcinoma, Pituitary desensitisation before ovulation induction with gonadotrophins, Breast Cancer, Endometriosis

Adult Dose

Subcutaneous Palliative treatment of prostatic carcinoma Adult: 3.6 mg injected into the anterior abdominal wall every 28 days or 10.8 mg every 12 wk. An anti-androgen is given several days before beginning of the treatment and continued for at least 3 wk to prevent disease flare. Pituitary desensitisation before ovulation induction with gonadotrophins Adult: 3.6 mg as a depot inj. Monitor serum-oestradiol concentrations until they decline to levels similar to those in the early follicular phase which takes about 7-21 days.

Child Dose

Renal Dose

Administration

Contra Indications

Hypersensitivity; pregnancy, lactation.

Precautions

Urinary tract obstruction or spinal cord compression (when used for prostate cancer); decreased bone density in women. Contraceptive measures should be taken to protect against pregnancy. Monitor men at risk from tumour flare during the 1st mth of therapy. Safety and efficacy on the usage of the 10.8 mg implant in women is not established. Lactation: excretion in milk unknown; not recommended

Pregnancy-Lactation

Pregnancy Category: D (advanced breast cancer); X (endometriosis, endometrial thinning) Lactation: excretion in milk unknown; not recommended

Interactions

Adverse Effects

Side effects of Goserelin : >10% Flushing (46-96%), Vaginitis (5-75%), Hot flashes (62%), Reduced libido (47-61%), Mood swings (60%), Depression (women 54%), Sweating (16-45%), Acne (42%), Diarrhea (40%), Breast atrophy (33%), Headache (women 32-75%), Seborrhea (26%), Tumor flare (23%), Sexual dysfunction (21%), Peripheral edema (21%), Erectile dysfunction (18%), Pain (8-17%), UTI (13%) 1-10% Nausea (9%), Lethargy (8%), Rash (6%), Chronic obstructive pulmonary disease (5%), Congestive heart failure(5%), Cerebrovascular accident (1-5%), Renal impairment (1-5%), Headache (men 1-5%), Depression (men 1-5%), Immune hypersensitivity reaction (>1%) Frequency Not Defined Asthenia, Hypercalcemia, Cystitis, Dysmenorrhea, Hirsutism, Dyspareunia, Breast changes, Implant site reactions, Bone pain, Spinal cord compression (rare)

Mechanism of Action

Goserelin is a potent inhibitor of pituitary gonadotrophin secretion. Initially, it causes an increase in the serum levels of FSH and LH but chronic admin will lead to sustained suppression of the pituitary gonadotrophin release causing regression of the sex organs.

Note

ZOLADEX DEPOT 3.6mg Injection / Subcutaneous manufactured by AstraZeneca UK Limited. Its generic name is Goserelin. ZOLADEX DEPOT is availble in United Arab Emirates. Farmaco UAE drug index information on ZOLADEX DEPOT Injection / Subcutaneous is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Goserelin :